Amarin Corp. PLC ADR (AMRN) News
Filter AMRN News Items
AMRN News Results
|Loading, please wait...|
AMRN News Highlights
- For AMRN, its 30 day story count is now at 8.
- Over the past 27 days, the trend for AMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about AMRN are DRUG, MS and HOUR.
Latest AMRN News From Around the Web
Below are the latest news stories about AMARIN CORP PLC that investors may wish to consider to help them evaluate AMRN as an investment opportunity.
TG Therapeutics, Inc. (TGTX) is an unfortunate story for investors. Just like with Amarin Corporation plc (AMRN), the investment logic here was sound, however, it was ruined by random events. In Amarin's case, we had one approval, one major label expansion, and then along came Judge Du. In TG's case, we had one small approval, one major new approval on the horizon, and then they were forced to withdraw the first drug from the market. This killed the buzz around the upcoming approval, which, as we always knew, was the ...
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. H.C. Wainwright 24th Annual Global Investment Conference (September 12-14th, 2022; New York, New York) Date/Time: September 12, 2022, 9:00 a.m. ET/ 1:00 p.m. GMT+1 Webcast: https://journey.ct
Amarin Corporation plc (NASDAQ: AMRN) announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo. Related: Amarin's New Vascepa Data Shows Significant Reduction
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- -- Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 28, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new RED
New data shows that Amarin Corporation plc's (NASDAQ: AMRN) Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes in patients with cardiovascular disease or diabetes with risk factors. The REDUCE-IT study data presented show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo. IPE also significantly reduced NSTEMI by 27%. Related: Amarin Still Suspends FY22
As of Friday before the market open, Amarin's stock was down by nearly 18% week to date, according to data provided by S&P Global Market Intelligence. Last Friday after market close, Amarin disclosed in a regulatory filing that it is ceasing operations in Germany, effective Sept. 1. The move comes after discussions with healthcare officials in that country failed to produce a reimbursement price Amarin considered "viable," in its words, for Vazkepa.
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced ST-segment elevation myo
Challenging market conditions make these growth stocks to sell a detriment to your portfolio if you don't dump them before Q4.
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV) event from the landmark REDUCE-IT® cardiovascular outcomes trial have been accepted for presentation at the European Society of Cardiology (ESC) Congress, both online and onsite in Barcelona, August 26-29, 2022.
H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Amarin (AMRN – Research Report) today and set a price target of $3.00. The company's shares closed last Thursday at $1.28, close to its 52-week low of $1.11. According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.2% and a 37.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. Amarin has an analyst consensus of Hold, with a price target consensus of $2.80, a 124.0% upside from current levels.